Key result
Neoadjuvant treatment with sorafenib for 6 months in a patient with advanced renal cell carcinoma led to a reduction in thrombus extension and over 90% necrosis of the renal mass.
Case Report (n=1)
Neoadjuvant sorafenib for 6 months reduced vena cava thrombus extension and induced >90% tumor necrosis in a patient with advanced renal cell carcinoma.
Hypothesis-generating for neoadjuvant sorafenib in advanced RCC with vena cava thrombus; prospective trials needed before any practice change.
A 71-year-old man with advanced left renal cell carcinoma (lymph node involvement and vena cava thrombus) was submitted to 6 months of neoadjuvant treatment with sorafenib before open radical nephrectomy. After sorafenib treatment and before surgery a new CT scan confirmed the presence of a 9.0 cm in diameter solid mass in the left kidney but a reduction in thrombus extension, limited to the left renal vein. At histological examination after radical nephrectomy, over 90% of the renal mass was substituted by necrotic tissue.
No takes yet. Share an insight, caveat, or question.
Silverio et al. (2008) conducted a case report in Advanced left renal cell carcinoma with vena cava thrombus (n=1). Sorafenib was evaluated on Tumor response and histological necrosis. Neoadjuvant treatment with sorafenib for 6 months in a patient with advanced renal cell carcinoma led to a reduction in thrombus extension and over 90% necrosis of the renal mass.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: